Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 290 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Spondylarthritis Clear all

Conditions: Ankylosing Spondylitis
Interventions: Placebo, Golimumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 11
States / cities: Glendale, Arizona • Mesa, Arizona • La Palma, California + 8 more

Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Interventions: bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • Fountain Valley, California • Tampa, Florida + 3 more

Conditions: Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions: Not listed
Lead sponsor: Brain Inflammation Collaborative; Other
Eligibility: 2 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Delafield, Wisconsin

Conditions: Arthritis, Psoriatic
Interventions: placebo, ustekinumab 45 mg, ustekinumab 90 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 22 more

Conditions: Ankylosing Spondylitis
Interventions: Sarilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 26
States / cities: Birmingham, Alabama • Anaheim, California • Los Angeles, California + 23 more

Conditions: Psoriatic Arthritis, Psoriasis, Psoriatic Conditions, Dermatologic Disease, Rheumatologic Disease, Psoriatic Nail, Plaque Psoriasis, Joint Pain, Dactylitis
Interventions: Participant self-assessment surveys, Psoriasis Draw, Psoriasis Area Photo, Finger and Toe Photos, Digital Jar Open, 30 Second Walk, Psorcast mobile application; Behavioral · Other
Lead sponsor: Sage Bionetworks; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Psoriatic Arthritis
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Psoriatic Arthritis
Interventions: SUNPG18_07 I (Tildrakizumab 200 mg), SUNPG18_07 II (Tildrakizumab 100 mg); Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 13
States / cities: Glendale, Arizona • Phoenix, Arizona • Denver, Colorado + 10 more

Conditions: Arthritis, Rheumatoid, Arthritis, Psoriatic, Psoriasis, Ankylosing Spondylitis, Autoimmune Diseases
Interventions: Root-cause autoimmune treatment program; Other
Lead sponsor: AndHealth; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Psoriatic Arthritis
Interventions: Ixekizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 22
States / cities: Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 19 more

Conditions: Arthritis
Interventions: Blood Draws for Serum Titers; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 9 Years to 26 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 4
States / cities: Chicago, Illinois • Cleveland, Ohio

Conditions: Anklyosing Spondylitis
Interventions: Secukinumab (75 mg), Placebo, Secukinumab (150 mg); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 10
States / cities: Mesa, Arizona • Upland, California • Edina, Minnesota + 6 more

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo, Adalimumab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Rancho Mirage, California • Duncansville, Pennsylvania

Conditions: Axial Spondyloarthritis
Interventions: Dietary recommendations; Other
Lead sponsor: Viome; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Bothell, Washington

Conditions: Spondylitis, Ankylosing
Interventions: MRI; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Spondylitis, Ankylosing
Interventions: golimumab, Golimumab (CNTO 148); placebo; Biological
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 11
States / cities: Paradise Valley, Arizona • Los Angeles, California • San Francisco, California + 8 more

Conditions: Psoriatic Arthritis
Interventions: Izokibep, Placebo to izokibep; Drug
Lead sponsor: ACELYRIN Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 40
States / cities: Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more

Conditions: Psoriatic Arthritis, Psoriasis
Interventions: Decision Aid; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Spondylitis, Ankylosing
Interventions: Secukinumab, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Anniston, Alabama • Upland, California • Aventura, Florida + 9 more

Conditions: Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA), Axial Spondyloarthritis and Ankylosing Spondylitis
Interventions: Not listed
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Psoriasis, Pregnancy, Psoriatic Arthritis, Crohn Disease
Interventions: Ustekinumab, Guselkumab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2031
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Psoriatic Arthritis
Interventions: AbGn-168H; Biological
Lead sponsor: AbGenomics B.V Taiwan Branch; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: La Jolla, California • Palo Alto, California • Sarasota, Florida + 4 more

Conditions: Psoriatic Arthritis
Interventions: Zasocitinib, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 19 more

Conditions: Psoriatic Arthritis (PsA)
Interventions: GLP-1 agonists, Nutrition Counseling; Drug · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

A Study of Golimumab in Participants With Active Ankylosing Spondylitis

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

Psorcast Mobile Study

DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

IMPACT - AndHealth Autoimmune Research Registry

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis

16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Microbiome and Axial Spondyloarthritis

Novel Quantitative MRI for Axial Spondyloarthritis

A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis

Psoriatic Arthritis Study of Izokibep

Psoriatic Arthritis and Psoriasis Treatment Decision Aid

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis

UCB Cimzia Pregnancy Follow-up Study

Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project

A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial